MoonLake Immunotherapeutics has reported significant financial results for the first quarter of 2026, revealing a net loss of $69.7 million, a 71.9% increase from the $40.6 million loss recorded in the same period of 2025. The company's total operating expenses rose to $70.0 million, up 47.5% from $47.5 million year-over-year, primarily driven by increased research and development costs associated with its clinical trials and manufacturing activities. Research and development expenses alone surged by 49.5% to $54.5 million, reflecting heightened investment in the development of its lead product candidate, Sonelokimab (SLK).
In terms of liquidity, MoonLake reported $357.9 million in cash, cash equivalents, and short-term marketable securities as of March 31, 2026. This figure represents a decrease from $421.7 million at the end of 2025, attributed to the company's ongoing operational expenditures. The company’s current assets exceeded its current liabilities by $350.5 million, indicating a solid liquidity position. MoonLake anticipates that its available capital will be sufficient to fund operations through the end of 2027, bolstered by recent equity sales under its at-the-market offering program.
Strategically, MoonLake is focused on advancing SLK, a tri-specific Nanobody targeting inflammatory skin and joint diseases. The company has made significant progress in its clinical trials, including positive results from the Phase 2b MIRA trial for hidradenitis suppurativa and ongoing Phase 3 trials (VELA-1 and VELA-2). The company is preparing to submit a Biologics License Application (BLA) for SLK in the second half of 2026, with a potential commercial launch in the U.S. expected in 2027, pending regulatory approval.
Operationally, MoonLake has expanded its workforce and infrastructure to support its clinical development efforts. The company has also established a new subsidiary, MoonLake Immunotherapeutics US Inc., to facilitate its planned commercial activities in the United States. As of March 31, 2026, the company had 72.1 million Class A Ordinary Shares outstanding, reflecting its ongoing efforts to raise capital through equity offerings.
Looking ahead, MoonLake expects to continue incurring substantial losses as it invests in the development of SLK and prepares for its commercial launch. The company remains focused on achieving regulatory approvals and expanding its clinical pipeline, while also managing its cash flow and operational expenditures to ensure financial sustainability in the coming years.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotech company focused on developing Nanobody-based therapies for inflammatory skin and joint diseases. Its lead product, SLK, targets IL-17A and IL-17F to treat conditions like hidradenitis suppurativa, psoriatic arthritis, and psoriasis. The company advances clinical trials, seeks regulatory approval, and aims for commercialization, leveraging proprietary technology, strategic licensing, and partnerships to address unmet medical needs in immunology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.